Pipeline Overview
BrainCells is focused on the development of our mGluR2/3 antagonism program for treatment resistant depression (TRD), major depressive disorder (MDD) and Alzheimer’s disease (AD) which is currently in Phase 1 development.
Non-strategic Assets
BrainCells has developed a number of additional compounds which are currently available for outlicensing.